Theriva Biologics (NYSEAMERICAN:TOVX – Get Free Report) released its earnings results on Tuesday. The company reported ($6.81) EPS for the quarter, missing analysts’ consensus estimates of ($6.25) by ($0.56), Zacks reports.
Theriva Biologics Price Performance
TOVX traded down $0.07 during midday trading on Thursday, hitting $1.35. The stock had a trading volume of 152,936 shares, compared to its average volume of 1,002,400. Theriva Biologics has a 1 year low of $1.24 and a 1 year high of $17.11. The firm has a market cap of $3.06 million, a P/E ratio of -0.04 and a beta of 1.34.
Analyst Ratings Changes
Separately, Maxim Group dropped their price objective on shares of Theriva Biologics from $25.00 to $6.00 and set a “buy” rating on the stock in a report on Wednesday.
About Theriva Biologics
Theriva Biologics, Inc, a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company’s lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors.
Further Reading
- Five stocks we like better than Theriva Biologics
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- 3 GARP Stocks Offering Strong Growth: Aptiv, Allstate, Barrick
- 3 Fintech Stocks With Good 2021 Prospects
- Mouse Rising: The Iger Investment Pays Off for Disney Investors
- Insider Selling Explained: Can it Inform Your Investing Choices?
- Can CAVA Stock Be the Next Chipotle? Earnings Can Help
Receive News & Ratings for Theriva Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theriva Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
